Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer
We studied the unique inhibitor of the histone deacetylases (HDAC) valproate-valpromide of acyclovir (AN446) that upon metabolic degradation release the HDAC inhibitor (HDACI) valproic acid (VPA). Among the HDAC inhibitors that we have tested, only AN446, and to a lesser extent VPA, synergized with...
Saved in:
Main Authors: | Nataly Tarasenko (Author), Harel Josef Wilner (Author), Abraham Nudelman (Author), Gania Kessler-Icekson (Author), Ada Rephaeli (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy
by: Jiang Yu, et al.
Published: (2020) -
Optimized 5-Fluorouridine Prodrug for Co-Loading with Doxorubicin in Clinically Relevant Liposomes
by: Debra Wu, et al.
Published: (2021) -
Ultrasound and Microbubbles Enhance Uptake of Doxorubicin in Murine Kidneys
by: Oystein Eikrem, et al.
Published: (2021) -
Simultaneous determination of doxorubicin and its dipeptide prodrug in mice plasma by HPLC with fluorescence detection
by: Jing Han, et al.
Published: (2016) -
A Nanomicellar Prodrug Carrier Based on Ibuprofen-Conjugated Polymer for Co-delivery of Doxorubicin
by: Zuojun Li, et al.
Published: (2018)